CAYSTON POWDER FOR SOLUTION
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
15-05-2020
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
AZTREONAM
Available from:
GILEAD SCIENCES CANADA INC
ATC code:
J01DF01
INN (International Name):
AZTREONAM
Dosage:
75MG
Pharmaceutical form:
POWDER FOR SOLUTION
Composition:
AZTREONAM 75MG
Administration route:
INHALATION
Units in package:
2ML
Prescription type:
Prescription
Therapeutic area:
MONOBACTAMS
Product summary:
Active ingredient group (AIG) number: 0122819004; AHFS:
Authorization status:
APPROVED
Authorization date:
2009-09-11
Summary of Product characteristics
PRODUCT MONOGRAPH
PR
CAYSTON
®
AZTREONAM FOR INHALATION SOLUTION
75 MG AZTREONAM / VIAL
ANTIBIOTIC
_(ATC J01DF01) _
_ _
_ _
_ _
_ _
_ _
Gilead Sciences, Inc.
Foster City, CA 94404
USA
Gilead Sciences Canada, Inc.
Mississauga, ON
L5N 2W3
www.gilead.ca
Control No.: 234938_ _
Date of Revision:
May 15, 2020
CAYSTON
(aztreonam for inhalation solution)
Product Monograph
2
TABLE OF CONTENTS
PART I.
HEALTH PROFESSIONAL INFORMATION
................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................................
9
DOSAGE AND ADMINISTRATION
........................................................................................................
10
OVERDOSAGE
..........................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
11
STORAGE AND STABILITY
....................................................................................................................
12
SPECIAL HANDLING
INSTRUCTIONS..................................................................................................
13
DOSAGE F
Read the complete document
